Partial treatment interruptions

Deeks, Steven G.; Martin, Jeffrey N.

doi:10.1097/coh.0b013e328011bb30

Cited by 3 publications

(1 citation statement)

References 104 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The available data suggest that the roles of these mechanisms differ according to the therapeutic drug class. 242,[246][247][248][249][250][251][252] Such information is especially relevant for heavily drug-experienced HIV-infected people with persistent viremia, for whom treatment options are often limited and for whom their clinicians have the dilemma of considering ''when to switch,'' ''how to switch,'' and ''how to wait.'' 251 However, because the ultimate goal of ART remains the maximal suppression of viremia and to indefinitely halt disease progression, this emphasizes the continued need to develop novel compounds or novel combination regimens that reduce the likelihood of resistance and bear the least cross-resistance with current regimens.…”

Section: Therapy: Treatment Of Infectionmentioning

confidence: 99%

The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies

Rompay

2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Several nonhuman primate models are used in HIV/AIDS research. In contrast to natural host models, infection of macaques with virulent simian immunodeficiency virus (SIV) isolates results in a disease (simian AIDS) that closely resembles HIV infection and AIDS. Although there is no perfect animal model, and each of the available models has its limitations, a carefully designed study allows experimental approaches that are not feasible in humans, but that can provide better insights in disease pathogenesis and proof-of-concept of novel intervention strategies. In the early years of the HIV pandemic, nonhuman primate models played a minor role in the development of antiviral strategies. Since then, a better understanding of the disease and the development of better compounds and assays to monitor antiviral effects have increased the usefulness and relevance of these animal models in the preclinical development of HIV vaccines, microbicides, and antiretroviral drugs. Several strategies that were first discovered to have efficacy in nonhuman primate models are now increasingly used in humans. Recent trends include the use of nonhuman primate models to explore strategies that could reduce viral reservoirs and, ultimately, attempt to cure infection. Ongoing comparison of results obtained in nonhuman primate models with those observed in human studies will lead to further validation and improvement of these animal models so they can continue to advance our scientific knowledge and guide clinical trials.

show abstract

Section: Therapy: Treatment Of Infectionmentioning

confidence: 99%

The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies

Rompay

2012

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

Wirden

Simon

Schneider

et al. 2009

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

All VL changes were well below the clinically relevant variation of 0.5 log copies/mL at the end of the interruption. Thus, this study indicates that, for viruses harbouring one of the two main resistance pathways described for raltegravir, no relevant antiviral activity seems to persist in vivo. Even if further observations would be useful to reinforce this conclusion, the cost/benefit and risk/benefit of maintaining raltegravir as part of a salvage regimen in the presence of raltegravir mutations seem debatable, especially in the absence of relevant antiretroviral activity in this context.

show abstract

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Micheel¹,

Ball²

2010

View full text Add to dashboard Cite

Partial treatment interruptions

Cited by 3 publications

References 104 publications

The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies

The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Contact Info

Product

Resources

About